doi:10.3389/fgene.2012.00273engAgúndez, J. A. G.Abad-Santos, F.Aldea, A.Alonso-Navarro, H.Bernal, M. L.Borobia, A. M.Borrás, E.Carballo, M.Carvajal, A.García-Muñiz, J. D.Gervasini,G.Jiménez-Jiménez,F. J.Lucena,M. I.Martínez,C.Sacristán,J. A.Salado,I.Sinués,B.Vicente,J.García-Martín,E.Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in SpainART-2012-80850The development of clinical practice recommendation sor guide lines forthe clinical use of biomarkersis an issue of great importance with regard to averse drug reactions. Thepoten-tial of pharmacogenomic biomarkers has been extensively investigate dinrecent years. However, several barriers to implementing the use of pharmacogenomics testing exist. We conducted asurvey among members of the Spanish Societies of Pharmacology and Clinical Pharmacology to obtain in format in about the perception of uch barrier sand to compare the perceptions of participants about the relative importance of ma jorgene/drug pairs. Of 11 potential barriers, the highest importance was attributed to lack of institutional support for pharmacogenomics testing, and to the issues related to the lackof guidelines. Of the proposed gene/drug pairs the highest importance was as signed to HLA-B/abacavir, UGT1A1/irinotecan, andCYP2D6/tamoxifen. In this perspective article, we compare there lative importanceof 29 gene /drug pairs in the Spanish study witht hat of the same pair sinthe American Society for Clinical Pharmacology and Therapeutics study, and we provide suggestions and area soffocus to developaguide for clinical practice in pharmacogenomics testing.2012http://zaguan.unizar.es/record/12983710.3389/fgene.2012.00273http://zaguan.unizar.es/record/129837oai:zaguan.unizar.es:129837info:eu-repo/grantAgreement/ES/MICINN/FPI-CSD2009-00064info:eu-repo/grantAgreement/ES/MICINN/ISCIII-PS09-00469info:eu-repo/grantAgreement/ES/MICINN/ISCIII-PS09-00943Frontiers in Genetics 3, 273 (2012), 1-4byhttp://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccess